MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation.

MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation.
复制标题

MALT1 抑制作为 T 细胞急性淋巴细胞白血病的治疗策略,通过阻断 Notch1 诱导的 NF-κ B 激活

DOI:
10.3389/fonc.2020.558339
复制
发表时间:
2020
影响因子:
4.7
通讯作者:
Niu M
Niu M
中科院分区:
医学3区
文献类型:
--
作者:
Wang R;Zhang H;Xu J;Zhang N;Pan T;Zhong X;Zhang H;Yin L;Yao Y;Wu Q;Li Z;Liu X;Xu K;Niu M

文献摘要

参考文献

被引文献

相似文献

目前t细胞急性淋巴细胞白血病(T-ALL)的治疗主要基于高强度联合化疗,其副作用严重。因此,迫切需要开发新的靶向治疗方法来治疗T-ALL。在这项研究中,我们发现粘膜相关淋巴组织淋巴瘤易位蛋白1 (MALT1)是治疗T-ALL的一个新的有希望的治疗靶点。MALT1抑制剂MI-2显著抑制T-ALL细胞的生长、增殖和集落形成。此外,MI-2通过线粒体依赖途径诱导T-ALL细胞凋亡。在T-ALL小鼠模型中,MI-2显著降低了白血病负荷,延长了白血病小鼠的生存期。在机制上,MALT1抑制有效地阻断了基线和notch1诱导的介导T-ALL细胞存活的核因子κB通路的激活。总之,我们的研究结果强调了MALT1作为治疗T-ALL的一个有吸引力的靶点的潜在作用,并支持MI-2或其他MALT1抑制剂在T-ALL临床试验中的潜力。
Current treatment of T-cell acute lymphoblastic leukemia (T-ALL) is primarily based on high-intensity combination chemotherapy, which has serious side effects. Therefore, developments of novel targeted therapeutics are urgently needed for treatment of T-ALL. In this study, we found that mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a novel promising therapeutic target for treatment of T-ALL. MALT1 inhibitor MI-2 significantly suppressed the cell growth, proliferation, and colony formation of T-ALL cells. Furthermore, MI-2 induced cell apoptosis of T-ALL via a mitochondrial-dependent pathway. In a T-ALL mouse model, MI-2 significantly reduced leukemic burden and prolonged the survival of leukemia-bearing mice. Mechanistically, MALT1 inhibition effectively blocked both baseline and Notch1-induced activation of nuclear factor κB pathway, which mediates T-ALL cell survival. In conclusion, our results highlight the potential role of MALT1 as an attractive target for treatment of T-ALL and support the potential of MI-2 or other MALT1 inhibitors to clinical trials in T-ALL.
DOI: 10.3390/cancers2041838
发表时间: 2010-11-05
期刊: Cancers
影响因子: 5.2
作者:
Dos Santos NR;Ghezzo MN;da Silva RC;Fernandes MT
通讯作者: Fernandes MT
非小细胞肺癌中膜胆汁酸受体 TGR5 通过激活 JAK2/STAT3 信号通路驱动细胞生长和迁移
DOI: 10.1016/j.canlet.2017.10.017
发表时间: 2018-01-01
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Liu, Xueqing;Chen, Bi;Jiang, Handong
通讯作者: Jiang, Handong
DOI: 10.1126/science.1102160
发表时间: 2004-10-08
期刊: SCIENCE
影响因子: 56.9
作者:
Weng, AP;Ferrando, AA;Aster, JC
通讯作者: Aster, JC
DOI: 10.1111/bjh.14877
发表时间: 2017-10-01
影响因子: 6.5
作者:
Kuhlen, Michaela;Bleckmann, Kirsten;Chen-Santel, Christiane
通讯作者: Chen-Santel, Christiane
DOI: 10.1016/0092-8674(91)90111-b
发表时间: 1991-08-23
期刊: CELL
影响因子: 64.5
作者:
ELLISEN, LW;BIRD, J;SKLAR, J
通讯作者: SKLAR, J